SAREPTA THERAPEUTICS, INC. Payments of Stock Issuance Costs
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments of Stock Issuance Costs of $2.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $110.00K.
- SAREPTA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2025 was $2.39M.
- SAREPTA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2024 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2023 was $0.00.
| Period end | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 1 month as first filed | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.39M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $2.28M 10-Q · filed 2025-11-06 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | ||||
| 2021-10-31 | $26.50M 10-K · filed 2024-02-28 | ||||
| 2019-03-31 | $300.00K 10-K · filed 2022-03-01 | $400.00K 10-Q · filed 2019-05-08 | |||
| 2018-11-30 | $24.60M 10-K · filed 2021-03-01 | ||||
| 2017-09-30 | $20.00M 10-Q · filed 2017-11-01 | ||||
| 2017-07-31 | $20.00M 10-K · filed 2020-02-26 | ||||
| 2016-09-30 | $17.60M 10-K · filed 2019-02-28 | ||||
| 2016-06-30 | $200.00K 10-K · filed 2019-02-28 | ||||
| 2015-10-31 | $6.80M 10-K · filed 2018-03-01 | ||||
| 2014-04-30 | $6.20M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |